Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03877536
Other study ID # RV 392
Secondary ID WRAIR 2393
Status Withdrawn
Phase N/A
First received
Last updated
Start date March 17, 2019
Est. completion date September 14, 2025

Study information

Verified date April 2019
Source Henry M. Jackson Foundation for the Advancement of Military Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the virologic effect, safety and tolerability of Genvoya® in adults during early acute HIV infection.


Description:

This is a prospective, open-label study to describe the effects of early antiretroviral (ART) therapy on 1) viral load, 2) safety and tolerability of Genvoya®, 3) clinical outcomes and secondarily on HIV-specific immune responses. This study is a sub-study of RV 217 that will recruit participants with incident HIV diagnoses from the parent RV 217 cohort. Potential RV 392 volunteers will be recruited from the RV 217 ECHO cohort if they have been diagnosed with incident HIV Infection. Screening procedures for HIV in RV 217 are designed to identify participants during acute HIV infection (AHI) or early HIV infection. Participants will initiate Genvoya®, a once a day antiretroviral pill within 1 week of enrollment. RV 392 follow-up visits will largely overlap with RV 217 visits for the study duration of 96 weeks, but additional visits will occur early after initiation of Genvoya®. RV 392 participants will remain co-enrolled in RV 217 (i.e., RV 217 visits also continue); blood collection will be coordinated by the RV 392 team by prioritizing safety labs and then research labs within the allotted blood volumes while still meeting scientific objectives for both RV 217 and RV 392. Blood tests that are required for both protocols will only be collected once and will not be duplicated across the two protocols.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 14, 2025
Est. primary completion date September 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. First identified as an incident HIV infection within one year of estimated time of infection in RV 217.

2. Willing to begin Genvoya® as soon as entering this study but not later than 7 days from study enrollment.

3. Successfully passed Test of Understanding (TOU) with a score of 80% or more on ten questions after three attempts.

4. Adult from 18 to 50 years of age.

5. Able to participate for 96 weeks of study visits

6. In general good health as determined by the PI or his/her designee

7. Willing to have photo or fingerprint taken for identification purposes

8. No history of ART for any reason, i.e., treatment naïve and no HIV-post-exposure prophylaxis (PEP) or HIV-pre-exposure prophylaxis (PrEP)) within 90 days prior to enrollment

9. Willing to have blood samples collected and stored.

10. Adequate renal function: estimated creatine clearance of >50 mL/min according to the Cockroft Gault formula 2 weeks prior to enrollment

11. Urine clean catch: glucose < trace and protein <1+ or as per site-specification 2 weeks prior to enrollment

12. Weight is > 35 kg

13. Female (only women of childbearing potential) Specific Criteria:

Negative pregnancy test 48 hours prior to enrollment:

Commits to continued use of adequate birth control method for 96 weeks of the study and prior to receiving study ART. Adequate birth control is defined as follows: Contraceptive medications delivered orally, intramuscularly, vaginally, or implanted, underneath the skin, surgical methods (hysterectomy or bilateral tubal ligation), condoms, diaphragms, intrauterine device (IUD), or abstinence. If depending on hormonal contraception, check package insert for drug interactions and/or consider adding a second barrier method.

Exclusion Criteria:

1. Any chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the volunteer, including but not limited to chronic hepatitis, renal insufficiency or failure; clinically significant forms of drug or alcohol abuse, mental illness, severe asthma, psychiatric disorders, heart disease, or cancer; or a physical finding on examination considered indicative of significant disease such as murmur (other than functional), hepatosplenomegaly, focal neurological deficit, etc.

2. Untreated AIDS-related opportunistic infection

3. An AIDS defining condition diagnosed within 30 days

4. Positive Hepatitis B surface antigen at any time in the past

5. Requiring use of any medication that is contraindicated with Genvoya®. See Appendix I and the package insert

6. Women who are breast-feeding

There are no inclusion/exclusion criteria based on CD4 count because CD4 count can be transiently diminished during acute HIV infection and ART initiation during early or acute HIV infection offers the potential benefit of limiting reservoir seeding and preventing immune destruction regardless of peripheral CD4 count at the time of treatment initiation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Participants will receive 1 tablet per day throughout study duration (96 weeks).

Locations

Country Name City State
Uganda Makerere University--Walter Reed Project (MUWRP) Kampala

Sponsors (2)

Lead Sponsor Collaborator
Henry M. Jackson Foundation for the Advancement of Military Medicine Gilead Sciences

Country where clinical trial is conducted

Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in HIV-specific immune responses over time Description of changes in HIV-specific immune responses over time as characterized by intracellular cytokine staining (ICS) Measured through week 96
Other Host humoral (IgG) responses Characterization of evolution in host humoral (IgG) responses to HIV envelope over time including development of neutralizing antibody responses Measured through week 96
Other Markers of Immune Activation Description of markers of immune activation (soluble and cellular markers) by ICS. Measured through week 96
Other HIV reservoir size Evaluation of the HIV reservoir size by measurement of 1) single copy HIV RNA quantification in samples with HIV RNA <50 copies/mL and 2) total HIV DNA and integrated HIV DNA in peripheral blood Measured through week 96
Other Neuropsychological battery performance Evaluation of neuropsychological battery performance at week 48 and 96; and to later compare to RV 217 data from pre-infection and baseline early or acute HIV infection timepoints. Measured through week 96
Primary Plasma viral load The number of study participants with plasma viral load <50 copies/mL Measured at 48 weeks after enrollment
Primary Plasma viral load The number of study participants with plasma viral load <50 copies/mL Measured at 96 weeks after enrollment
Primary Drug-related AEs and SAEs Occurrence of drug-related adverse events and serious adverse events at any time from enrollment up to 96 weeks after enrollment early HIV infection. Measured through week 96
Primary Treatment Discontinuation for AEs up to 96 weeks Tolerability of treatment as measured by treatment discontinuation for AEs up to 96 weeks Measured through week 96
Secondary CD4+ T cell count change CD4+ T cell count change over first 48 weeks as compared to baseline.following the initiation of Genvoya® Measured over 48 weeks
Secondary Frequency of HIV-related illnesses Frequency of HIV-related illnesses (including acute retroviral syndrome) Measured through week 96
Secondary Duration of HIV-related illnesses Duration of HIV-related illnesses (including acute retroviral syndrome) Measured through week 96
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2